Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism in ST elevation acute myocardial infarction in young patients less than 45 years

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Protocol for a prospective, controlled study of assertive and timely reperfusion for patients with ST-segment elevation myocardial infarction in Tamil Nadu: the TN-STEMI programme

  2013influential reference
• Biomarkers in acute myocardial infarction

  2010cited by this paper
• Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients.

  2009cited by this paper
• Biomarkers in Acute Coronary Syndrome

  2008cited by this paper
• The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase

  2008cited by this paper
• Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study

  2007cited by this paper
• An Effect of the PAI-1 4G/5G Polymorphism on Cholesterol Levels May Explain Conflicting Associations with Myocardial Infarction and Stroke

  2006cited by this paper
• Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.

  2006cited by this paper
• Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women

  2005cited by this paper
• Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction.

  2005cited by this paper
• The future of association studies: gene-based analysis and replication.

  2004cited by this paper
• Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters.

  2004cited by this paper
• Detecting Disease Associations due to Linkage Disequilibrium Using Haplotype Tags: A Class of Tests and the Determinants of Statistical Power

  2003cited by this paper
• PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction

  2003cited by this paper
• Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality

  2003cited by this paper
• Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study

  2003cited by this paper
• Choosing Haplotype-Tagging SNPS Based on Unphased Genotype Data Using a Preliminary Sample of Unrelated Subjects with an Example from the Multiethnic Cohort Study

  2003cited by this paper
• Plasminogen activator inhibitor 1: physiological and pathophysiological roles.

  2002cited by this paper
• Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients.

  2001cited by this paper
• Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis.

  2001cited by this paper
• Haplotype tagging for the identification of common disease genes

  2001cited by this paper
• The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.

  2000cited by this paper
• The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.

  2000cited by this paper
• The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

  2000cited by this paper
• Plasminogen-activator inhibitor type 1 and coronary artery disease.

  2000cited by this paper
• Emerging epidemic of cardiovascular disease in developing countries.

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• The 4G4G Genotype of the Plasminogen Activator Inhibitor 4G/5G Gene Polymorphism Is Associated with Coronary Atherosclerosis in Patients at High Risk for this Disease

  1999cited by this paper
• Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

  1998cited by this paper
• Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene

  1998cited by this paper
• 4G/5G Promoter PAI-1 Gene Polymorphism Is Associated with Plasmatic PAI-1 Activity in Italians: A Model of Gene-Environment Interaction

  1998cited by this paper
• PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.

  1998cited by this paper
• Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population.

  1998cited by this paper
• Coronary heart disease: outlook for Africa

  1997cited by this paper
• Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

  1997cited by this paper
• Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

  1997cited by this paper
• PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events

  1997cited by this paper
• Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo.

  1997cited by this paper
• Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population.

  1997cited by this paper
• A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.

  1996cited by this paper
• Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study.

  1995cited by this paper
• Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene

  1995cited by this paper
• Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes

  1995cited by this paper
• Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

  1995cited by this paper
• The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study

  1995cited by this paper
• Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.

  1995cited by this paper
• The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

  1993cited by this paper
• Genetic markers

  1993cited by this paper
• Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis.

  1991cited by this paper
• Impaired fibrinolysis and risk of thromboembolism.

  1991cited by this paper
• Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

  1991cited by this paper
• Harrison's Principles of Internal Medicine

  1988influential reference
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper

• No citing papers are available for this paper.